Decision regret following rapid genetic testing at the time of breast cancer diagnosis
Cancer · 01.11.2026 · 132 (21)
DOI: 10.1002/cncr.70663 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, online erschienen am 01.11.2026. Verfasst von Ling-Fang Hsu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Genetic Testing, Decision Making, Emotions. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Women's College Hospital Foundation, Peter Gilgan Centre for Women's Cancer, CIHR.
Abstract (Originalsprache)
Introduction
Genetic testing is increasingly being offered at the time of breast cancer diagnosis to help women guide their treatment decisions. The objective of the current study was to measure decision regret 1 year after genetic testing and to evaluate the factors associated with regret.
Methods
Women from across Canada were referred to receive rapid genetic testing for breast cancer predisposition genes at the time of breast cancer diagnosis ( BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, TP53, ATM, and CHEK2) . Questionnaires were completed prior to testing and 1‐week and 1‐year postgenetic testing. Decision regret was measured at one‐year.
Results
Overall, 871 women participated and the mean age at diagnosis was 46.0 years (range 19–70 years), and 522 (59.9%) of the women were White. Pathogenic variants were found in 83 women (9.5%). The mean score for decision regret was 7.86 (SD 14.17), with 802 women (92.1%) having no regret and 69 participants (7.9%) having regret. Women from racialized groups were more likely to regret their decision compared to White women (13.4% vs 4.4%; p < .001). Those with a BRCA1 or BRCA2 pathogenic variant were significantly more likely to have regret compared to those with a negative result ( p = .03).
Conclusion
A minority of women who have rapid genetic testing at the time of breast cancer diagnosis later regret their decision. Women at greater risk of having decision regret included those who received a positive BRCA1 or BRCA2 genetic test, and those from racialized groups. Follow‐up counseling may be warranted for those who experience decision regret.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lawrence S. Bloomberg Faculty of Nursing, University of Toronto, Toronto, Ontario, Canada.
- Women's College Research and Innovation Institute, Toronto, Ontario, Canada.
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Royal Victoria Regional Health Centre, Barrie, Ontario, Canada.
- Trillium Health Centre, Mississauga, Ontario, Canada.
ORCID-Profile: David W Lim, Steven Narod, Kelly Metcalfe
Förderung
- Women's College Hospital Foundation
- Peter Gilgan Centre for Women's Cancer
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Hsu, L. F., Eisen, A., Poll, A., Lim, D. W., Wright, F. C., Hanrahan, R., Hosein, A., Pal, T., Narod, S., & Metcalfe, K. (2026). Decision regret following rapid genetic testing at the time of breast cancer diagnosis. Cancer, 132(21). https://doi.org/10.1002/cncr.70663
Vancouver
Hsu LF, Eisen A, Poll A, Lim DW, Wright FC, Hanrahan R, et al. Decision regret following rapid genetic testing at the time of breast cancer diagnosis. Cancer. 2026;132(21). doi:10.1002/cncr.70663
BibTeX
@article{Hsu2026,
author = {Hsu, Ling-Fang and Eisen, Andrea and Poll, Aletta and Lim, David W and Wright, Frances C and Hanrahan, Renee and Hosein, Alana and Pal, Tuya and Narod, Steven and Metcalfe, Kelly},
title = {Decision regret following rapid genetic testing at the time of breast cancer diagnosis},
journal = {Cancer},
year = {2026},
volume = {132},
number = {21},
doi = {10.1002/cncr.70663}
}
EUVIMED